STOCK TITAN

Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Intellia Therapeutics, Inc. director Fred E. Cohen received new equity-based compensation. He was granted 9,200 restricted stock units, each representing a contingent right to one share of Intellia common stock, increasing his direct common stock holdings to 216,653 shares.

He was also granted a stock option covering 13,300 shares of common stock at an exercise price of $12.89 per share. This option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders, and expires on June 8, 2036.

Positive

  • None.

Negative

  • None.
Insider Cohen Fred E
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 13,300 $0.00 --
Grant/Award Common Stock 9,200 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 13,300 shares (Direct); Common Stock — 216,653 shares (Direct)
Footnotes (1)
  1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
RSUs granted 9,200 units Restricted stock units granted June 9, 2026
Option shares granted 13,300 shares Stock option grant June 9, 2026
Option exercise price $12.89 per share Stock option on 13,300 shares
Shares held after grant 216,653 shares Common stock directly owned after RSU grant
Option expiration date June 8, 2036 Expiry of 13,300-share stock option
restricted stock units financial
"Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy) financial
"Stock Option (right to buy) with respect to 13,300 shares of Common Stock"
exercise price financial
"conversion or exercise price of 12.8900 per share for the stock option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests in full financial
"This option was granted ... and vests in full on the earlier to occur of the first anniversary"
annual meeting of stockholders financial
"vests in full on the earlier to occur of the first anniversary or the date of the next annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transactions did Intellia Therapeutics (NTLA) report for Fred E. Cohen?

Intellia reported that director Fred E. Cohen received equity awards, not open-market trades. He was granted 9,200 restricted stock units and a stock option for 13,300 shares, both dated June 9, 2026, as part of his compensation.

How many shares does Fred E. Cohen hold after the latest NTLA Form 4 filing?

After the reported grant, Fred E. Cohen directly holds 216,653 shares of Intellia common stock. He also holds a stock option covering 13,300 additional shares, which represents a separate right to buy shares at a fixed exercise price.

What stock option did Fred E. Cohen receive from Intellia Therapeutics (NTLA)?

Fred E. Cohen received a stock option for 13,300 shares of Intellia common stock at an exercise price of $12.89 per share. The option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting.

When do Fred E. Cohen’s new Intellia (NTLA) stock options expire?

The new Intellia stock option granted to Fred E. Cohen expires on June 8, 2036. This long-dated option provides a right to buy 13,300 shares at $12.89 per share, once it fully vests according to the disclosed vesting schedule.

What are the restricted stock units granted to Fred E. Cohen by Intellia Therapeutics?

The filing states that 9,200 restricted stock units were granted, each representing a contingent right to receive one share of Intellia common stock. These units are a form of equity compensation that converts into shares when vesting conditions are satisfied.

Were Fred E. Cohen’s Intellia (NTLA) transactions open-market purchases or sales?

The transactions were not open-market trades. The Form 4 describes them as grants or awards, with zero purchase price per share, indicating compensation-related acquisitions of restricted stock units and stock options rather than market buying or selling.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cohen Fred E

(Last)(First)(Middle)
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130

(Street)
CAMBRIDGE MASSACHUSETTS 02139

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)06/09/2026A9,200A$0.00216,653D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$12.8906/09/2026A13,300 (2)06/08/2036Common Stock13,300$0.0013,300D
Explanation of Responses:
1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
2. This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
James Basta, attorney-in-fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)